Long-term prostate cancer data illuminates risk and survival needs

The researchers followed the patient up to 30 years and found that the risk of dying from prostate cancer depended on how aggressive the cancer was in the diagnosis, according to the recent findings from the investigation that was shared at the annual meeting 2025 of the American Urological Association.

This investigation examined the long -term results for over 62,000 men in Sweden, in which metastatic prostate cancer was not diagnosed and which were treated in the current guidelines. In men with prostate cancer with little risk, the 30-year risk of dying from the disease was around 12%, while for people with very risky cancer, around 30%was. Most men, regardless of the risk, rather die from other causes.

In order to further discuss this topic, Dr. Pietro Scilipoti at the annual meeting for an interview with Cure. In the interview, he discussed the importance of these results and dealt with potential side effects or changes in the quality of life in patients with prostate cancer.

Scilipoti is clinical researcher and urology at the Vita-Salute San Raffaele University in Milan, Italy.

Transcript:

Healing: What should patients know about the potential side effects or changes in the quality of life based on the treatment of prostate cancer recommended by the directive due to the long -term results?

Well, that's a very, very important and timely question, because at the moment we are looking at decisions and quality of life in patients, and I think it really depends on it. Unfortunately we have no data in this special study [just yet]. However, I think that it is important to know that it has to experience certain changes that patients experience in life, and that they have to be prepared if they decide on radical treatment or receive radiation therapy.

As a clinician, we then have to follow these patients to help them improve their quality of life. I think communication between the patient and pastor and the communication of doctors is very important in this context.

The transcript was processed out of clarity and confidence.

You will not find any further news about cancer updates, research and education to subscribe to the Cure® newsletter.